Want to see HK:3347 full AI Analyst Report?
3347 Stock Chart & Stats
HK$54.00
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$54.00
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$28.12 - HK$59.90
Previous CloseN/A
Volume678.40K
Average Volume (3M)2.64M
Market Cap
HK$43.67B
Enterprise ValueHK$39.04K
Total Cash (Recent Filing)HK$2.20B
Total Debt (Recent Filing)HK$1.53B
Price to Earnings (P/E)56.2
Beta1.80
Next Earnings
Aug 29, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)0.90
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$55.33Price Target Upside2.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.24
Revenue Forecast (FY)HK$8.87B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low net leverage (debt ~7% of equity) provides durable financial flexibility. Over the next 2–6 months this supports funding for clinical programs, selective business development, and resilience to slower contract timing without needing dilutive financing or causing credit stress.
Positive And Growing Free Cash FlowSustained positive free cash flow that tracks most reported earnings indicates real cash generation capability. This supports reinvestment in operations, capacity to fund longer clinical trials, and reduces dependency on external capital, a durable strength for CROs with lumpy contract timing.
Stabilized Profitability And Revenue MomentumMargins stabilizing at mid-teens and modest revenue growth reflect an ability to maintain pricing and operational control after earlier cycles. For a service-led CRO, sustained mid-teens operating margins underpin long-run cash flow generation and competitive delivery capability.
Bears Say
Weakened Returns On EquityROE near 4% signals lower capital efficiency versus prior peak years. Persistently weak returns make it harder to justify reinvestment or organically fund higher growth without higher margins, and may limit long-term shareholder returns if efficiency doesn't improve.
Inconsistent Cash ConversionLess consistent conversion of accrual earnings into operating cash increases risk around funding project-intensive activities. For CROs with milestone billing and project timing variability, unreliable cash conversion can constrain hiring, scalability, and ability to absorb longer trial cycles.
Revenue And Margin VolatilityHistorical revenue decline and margin weakness indicate exposure to cyclical client demand and project timing. That structural volatility complicates forecasting, could force pricing pressure in slower periods, and raises the bar for delivering steady long-term growth.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$28.12 and its highest was HK$59.90 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$43.67B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Aug 29, 2026 which is in 20 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.069 earnings per share for the quarter, missing the consensus estimate of HK$0.274 by -HK$0.205.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.145 which represents an annual dividend yield of 0.38%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.28.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of HK$0.069 in its last earnings report, missing expectations of HK$0.274. Following the earnings report the stock price went up 3.772%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$55.33 (2.47% Upside)
HK$55.33 (2.47% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
0.38%
Trailing 12-Months
Asset Growth
-1.34%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
3347 Stock 12 Month Forecast
Average Price Target
HK$55.33
▲(2.47% Upside)
Technical Analysis
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
ADICON Holdings Limited
―
WuXi XDC Cayman, Inc.
―